Exparel 266 MG/20 ML vial 20ML
Ended Awarded
- Contract number
- SPE2DB25FDRBY
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $45,191
Award facts
- Contract value 100% obligated
- $45,191.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. The delivery order, valued at approximately $45,191, was issued on September 23, 2025, with an ultimate completion date of October 15, 2025, under firm fixed-price terms. This award represents a no-set-aside competitive procurement issued against DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million pharmaceutical supply vehicle valid through November 2026. EXPAREL is a liposomal bupivacaine formulation used for infiltration and nerve block anesthesia in surgical and medical procedures.
DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, leveraging its 24-year registration history in the System for Award Management to distribute branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare facilities nationwide. The company's robust portfolio of federal contract awards demonstrates consistent capability in delivering specialized pharmaceutical products, from oncology treatments and vaccines to anesthetics and injectable medications. The SPE2DB Indefinite Delivery Contract vehicle enables the DLA to efficiently procure pharmaceutical supplies across multiple product categories through firm fixed-price delivery orders, ensuring reliable access to essential medical supplies for military health facilities worldwide.
Quick answers
Who was awarded contract SPE2DB25FDRBY?
SPE2DB25FDRBY was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 23, 2025.
How much is contract SPE2DB25FDRBY worth?
The government has obligated $45,191 on SPE2DB25FDRBY.
Is contract SPE2DB25FDRBY an order under another contract?
Yes. SPE2DB25FDRBY is a delivery order under SPE2DB24D9238, an indefinite delivery contract.
Was contract SPE2DB25FDRBY competed?
The extent of competition for SPE2DB25FDRBY was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award